大股东持续反对，盟科药业定增易主事项折戟

Core Viewpoint - Mengke Pharmaceutical (688373) has decided to terminate its plan for a private placement of shares due to significant opposition from major shareholders and board members, despite initial approval from the shareholders' meeting [1][3][4]. Group 1: Termination of Private Placement - The company planned to issue 164 million shares to Nanjing Haiqing Pharmaceutical Co., Ltd. to raise 1.033 billion yuan, intended for daily R&D and operational investments [3]. - The termination was influenced by ongoing disagreements between major shareholder Genie Pharma and the company's management, which could potentially impact the company's stable operations [3][4]. - The company will negotiate with Haiqing Pharmaceutical regarding the termination of related agreements and will fulfill its information disclosure obligations as progress occurs [3]. Group 2: Opposition and Concerns - Initial opposition to the private placement came from board member Zhao Yachao, who raised concerns about the fairness and rationale of the transaction, citing the lack of direct operational experience of Haiqing Pharmaceutical in the anti-infection field [4]. - Genie Pharma expressed concerns that Haiqing Pharmaceutical's debt financing could significantly increase its debt ratio, potentially jeopardizing control stability and the company's independence [5]. Group 3: Financial Performance - Mengke Pharmaceutical has not yet achieved profitability; however, it reported a reduction in net losses due to the market penetration of its core product, Contizolam [7]. - For the first three quarters of the year, the company achieved approximately 104 million yuan in revenue, a year-on-year increase of 6.58%, while the net loss was approximately 194 million yuan, improved from a loss of 291 million yuan in the same period last year [7]. Group 4: Future Financing Plans - Following the termination of the private placement, the company plans to explore various financing channels, including engaging new strategic investors and issuing shares to unspecified parties, to support its long-term development [6]. - The current market sentiment remains supportive of innovative pharmaceutical companies, although investors are increasingly cautious about companies without clear profitability paths [6].